325 results on '"Verheijen J"'
Search Results
52. Adenoviral Gene Transfer of a u-PA Receptor-binding Plasmin Inhibitor and Green Fluorescent Protein: Inhibition of Migration and Visualization of Expression
53. 2-5A-PNA Complexes: A Novel Class of Antisense Compounds
54. Effects of TIMP-1 and TIMP-3 gene transfer on invasiveness, proliferation and apoptosis of rheumatoid arthritis (RA) synovial fibroblasts (RA-SF)
55. 33. Generation and characterization of transgenic mice with overexpression of fibrinogen B??-chain mRNA
56. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis
57. Dictionary of plant names in the lesser Sunda Islands
58. Fibrinogen and atherosclerosis: a study in transgenic mice
59. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells
60. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis
61. 24. Fibrinogen and atherosclerosis: a study in transgenic mice
62. 17. Fibrinogen and atherosclerosis: a study in transgenic mice
63. DIFFERENCE IN EXPRESSION OF THE PLASMINOGEN ACTIVATION SYSTEM IN SYNOVIAL TISSUE OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS
64. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator
65. Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin.
66. Properties of metastasizing and non-metastasizing human melanoma cell lines
67. Thrombolytic Properties in a Rabbit Jugular Vein Thrombosis Model of a Tissue-type Plasminogen Activator Mutant Lacking the Growth Factor- and Kringle 1-Domains
68. Recycling of poly(ethylene terephthalate) (PET)
69. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
70. Cell surface plasminogen activation is required for in vitro differentiation of human adult myogenic cells
71. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms.
72. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels.
73. Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig.
74. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig.
75. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.
76. Plasminogen Activators and Gastrointestinal Neoplasms.
77. Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
78. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.
79. Indicators of depressed fibrinolytic activity in pre-operative prediction of deep venous thrombosis.
80. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
81. DIFFERENCE IN EXPRESSION OF THE PLASMINOGEN ACTIVATION SYSTEM IN SYNOVIAL TISSUE OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS.
82. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor.
83. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
84. Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
85. Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial.
86. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surfacetargeted plasmin inhibitor
87. Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin
88. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
89. Daytime Fluctuations in Blood of Tissue-Type Plasminogen Activator (t-PA) and Its Fast-Acting Inhibitor (PAI-1)
90. A Novel and Simple Immunocapture Assay for Determination of Gelatinase-B (MMP-9) Acitivities in Biological Fluids: Saliva from Patients with Sjoegren's Syndrome Contain Increased Latent and Active Gelatinase-B Levels
91. Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults
92. Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma
93. Fibrinolytic Activators and Inhibitors in Terminal Renal Insufficiency and in Anephric Patients
94. A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma
95. Quantification of tissue-type plasminogen activator (t-PA) mRNA in human endothelial-cell cultures by hybridization with a t-PA cDNA probe
96. The role of the lysyl binding site of tissue-type plasminogen activator in the interaction with a forming fibrin clot.
97. Plasminogen Activators in the Intestine of Patients with Inflammatory Bowel Disease
98. Plasminogen activators in human colorectal neoplasia
99. Plasminogeenactivatoren in adenocarcinomen van het colon
100. The Sama/Bajau language in the lesser Sunda Islands
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.